A Memphis police officer ran a red light, causing a car crash. The officer had an expired drivers license. Here's what else ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval ...

Q3 2025 Earnings Call Transcript July 14, 2025 Simulations Plus, Inc. beats earnings expectations. Reported EPS is $0.45, ...

Breastfeeding did not appear to be associated with a higher risk of developing locoregional recurrences or contralateral breast cancers,” researchers wrote.

Researchers have found in a 3-year phase 3 trial that palopegteriparatide (TransCon PTH) showed sustained improvements in ...

PepsiCo, Inc. (NASDAQ:PEP) is making bold operational shifts across its global portfolio as it navigates shifting demand ...

PSFF consistently delivers lower risk and some upside, justifying its lower returns versus the S&P 500. Read more on PSFF ETF ...

Investing.com -- Cogent Biosciences, Inc. (NASDAQ: COGT) stock surged 10% after announcing positive top-line results from its SUMMIT trial of bezuclastinib in patients with non-advanced systemic ...

Guidance was raised from $7.60–$7.90 EPS to $7.75–$8, now inclusive of tariffs. Margin expansion guidance increased from "upside to the midpoint" to a specified "150 to 200 basis points" for the year.

A trial testing a nerve-sparing (NeuroSAFE) technique in radical prostatectomy may improve patient-reported outcomes.

July 10, 2025The Simply Good Foods Company reports earnings inline with expectations. Reported EPS is $0.51 EPS, expectations ...

ALZHEIMER’S disease (AD), a neurodegenerative condition marked by cognitive decline and progressive memory loss, has long been associated with chronic inflammation and immune dysregulation. Regulatory ...